How Long Has Mounjaro Been on the Market? A Closer Look at Its Journey and Impact

Last reviewed: July 15, 2026

Last updated: July 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) entered the United States market in May 2022 as the first dual-action GLP-1 and GIP receptor agonist approved for chronic weight management. Its arrival represented a clinical milestone, as earlier single-action GLP-1 agents like semaglutide had already demonstrated substantial efficacy. Understanding Mounjaro's market trajectory helps patients evaluate whether this option aligns with their health goals.

When Did Mounjaro Launch and Get FDA Approval?

The U.S. Food and Drug Administration granted approval to Mounjaro on May 13, 2022, for weight management in adults with obesity or overweight conditions accompanied by weight-related health complications. This approval followed successful Phase 3 clinical trials that demonstrated superior weight loss compared to existing GLP-1 monotherapies. The drug became available to patients through pharmacy channels within weeks of approval.

Mounjaro's approval was expedited because tirzepatide addressed an unmet clinical need—a dual peptide mechanism that activates two hormone pathways simultaneously. Prior to this approval, patients seeking prescription weight loss therapy relied primarily on semaglutide-based treatments, which target only the GLP-1 receptor. The competitive landscape shifted dramatically once tirzepatide became accessible, forcing healthcare providers to reconsider treatment algorithms.

Tirzepatide Clinical Trial Results and Early Market Adoption

Clinical trials showed tirzepatide users achieved average weight losses of 20–22% over 72 weeks at maximum doses, substantially exceeding outcomes from semaglutide monotherapy studies conducted in similar populations. The SURMOUNT-1 trial enrolled 2,539 participants and demonstrated tirzepatide's dose-dependent efficacy, with higher doses producing greater weight reduction. These compelling results accelerated prescription volume immediately after market entry.

Within the first year post-launch, tirzepatide prescriptions reached millions despite initial supply constraints. Healthcare systems, weight management clinics, and compounding pharmacies recognized the clinical advantage and began offering tirzepatide to eligible patients. Insurance coverage expanded gradually, though many patients faced high out-of-pocket costs that limited early access. This gap in affordability created demand for alternative sources of tirzepatide formulations.

How Compounded Tirzepatide Expanded Patient Access

As branded Mounjaro faced supply limitations and elevated pricing in 2023–2024, licensed 503A compounding pharmacies began manufacturing tirzepatide under strict quality and safety oversight. Compounded tirzepatide offers the identical active ingredient as the brand-name version, allowing patients to access the same dual-action mechanism at substantially lower costs. PlexusDx sources compounded tirzepatide injection from licensed 503A pharmacies and offers it at $289/mo month-to-month, or from $249/mo on the 6-month plan with no insurance requirement.

The expansion of compounded tirzepatide has democratized access to this treatment class. Patients no longer face month-long wait lists or insurance denials when selecting a licensed compounding source. Compounded formulations maintain bioequivalence to branded Mounjaro while eliminating the premium manufacturing markup. PlexusDx serves all 50 states and accepts HSA and FSA funds, removing additional barriers to therapy initiation.

Tirzepatide's Market Evolution and Genetic Response Optimization

Since 2022, tirzepatide market share has grown from zero to competing directly with semaglutide as a first-line injectable option for weight loss. Healthcare providers increasingly recognize that dual-action therapy works better for certain patient populations, particularly those with insulin resistance or metabolic dysfunction. Real-world data from 2024 confirms tirzepatide's sustained effectiveness and demonstrates it maintains weight loss durability beyond two years of continuous use.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long has tirzepatide been available to the general public?

Tirzepatide received FDA approval in May 2022 and became available at U.S. pharmacies within weeks. Compounded versions from licensed 503A pharmacies expanded availability significantly in 2023–2024, eliminating insurance requirements and reducing costs. PlexusDx currently offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan with shipments to all 50 states.

Did tirzepatide perform better than semaglutide in clinical trials?

Yes. The SURMOUNT-1 trial demonstrated tirzepatide produced average weight losses of 20–22% versus approximately 17% with semaglutide in comparable study populations. Tirzepatide's dual GLP-1 and GIP receptor activation creates stronger appetite suppression and metabolic benefits. Individual response varies, which is why genetic testing can help identify whether tirzepatide or semaglutide optimizes your personal metabolic pathway.

Why is compounded tirzepatide more affordable than branded Mounjaro?

Licensed 503A compounding pharmacies manufacture tirzepatide without the marketing, distribution, and premium manufacturing costs associated with branded medications. PlexusDx sources these compounded formulations and passes savings directly to patients. At $289 per month flat (no flat per-compound pricing increases), compounded tirzepatide costs 40–60% less than typical branded Mounjaro retail prices.

Is compounded tirzepatide as safe and effective as branded Mounjaro?

Yes. Compounded tirzepatide from licensed 503A pharmacies contains the identical active ingredient formulated under FDA oversight and state pharmacy regulations. It achieves bioequivalence to branded Mounjaro while maintaining the same clinical efficacy demonstrated in SURMOUNT trials. PlexusDx partners exclusively with licensed 503A compounders to ensure quality and sterility standards.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Hers Mounjaro
• Hims Mounjaro
• Mounjaro For Hypertension
• Mounjaro For Endometriosis

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.